光银国际独家保荐麦迪卫康香港主板成功上市
2021-01-19光银国际
2021年1月19日，麦迪卫康健康医疗管理科技股份有限公司（以下简称“麦迪卫康”）（股票代号：2159.HK）成功在香港联合交易所主板挂牌上市。光银国际担任本次麦迪卫康IPO独家保荐人、独家全球协调人、联席账簿管理人及联席牵头经办人，助力麦迪卫康成功发行上市。本次发行受到了资本市场投资者非常热烈追捧，香港公开发售部分共接获超9.2万份申请，最终获得了167.75倍超额认购，孖展金额超34亿港元。
光银国际作为麦迪卫康上市独家保荐人，凭借在香港资本市场的深厚积累和专业勤勉的投行精神，在本次项目保荐执行、市场推介、监管沟通等方面起到了至关重要的作用。疫情期间，项目执行与市场推介均遇到了前所未有的挑战，光银国际团队迎难而上，牵头领导各中介机构团结奋战，克服了重重困难，协助客户于12月中旬顺利通过聆讯，并在极短时间内完成市场推介，专业高效的投行服务得到了客户与中介同行高度好评。
2020年12月末香港新股市场再掀IPO热潮，11只新股同时招股。面对激烈市场竞争，光银国际临危不乱，沉着应战，通过积极有效的推介策略，高效挖掘潜在订单需求，增强后期销售推动力，为麦迪卫康成功发行奠定坚实基础。光银国际团队在投资故事构造、投资者引入、股票销售等方面的优异表现，带动了资本市场对麦迪卫康热烈认购氛围，最终实现了百倍超额认购，协助客户成功完成了本次发行。
作为中国光大银行在香港全资设立的国际投资银行平台，光银国际一直关注并服务于中国新经济领域，致力成为连接中国领先企业与资本市场沟通合作的桥梁，携手助力更多的中国优质企业发展成长。此次助力麦迪卫康成功上市，是光银国际在创新医疗服务领域努力耕耘的结果。依托多样的业务产品和丰富的客户资源，光银国际将继续竭诚为中国企业提供包括保荐承销、财务顾问、资产管理等全方位的优质金融服务，助力中国新经济领先企业发展壮大。
On January 19, 2021, Mediwelcome Medical Technology Co., Ltd. ("Mediwelcome") (stock code: 2159.HK) was successfully listed on the main board of the Hong Kong Stock Exchange. CEB International acted as the Sole Sponsor, Sole Global Coordinator, Joint Bookrunner and Joint Lead Manager for the successful IPO of Mediwelcome. This issuance has been enthusiastically sought after by investors in the capital market. The Hong Kong public offering has received more than 92,000 applications, and was oversubscribed by 167.75 times. The margin amount exceeded HK$3.4 billion.
CEB International, as the sole sponsor for the listing of Mediwelcome, has played a pivotal role in the implementation of this project's sponsorship, market promotion, and regulatory communication by utilizing its professional services and vast resources in the Hong Kong capital market. Despite the many unprecedented challenges encountered during the pandemic, CEB International’s team led the intermediary agencies to overcome the difficulties, and assisted clients to pass the hearing smoothly in mid-December. The overall market promotion was completed in a short period, CEBI’s professional and efficient investment banking services were highly praised by clients and intermediary colleagues.
At the end of December 2020, the Hong Kong market reached another boom in IPO, and 11 IPOs were being offered at the same time. In the face of fierce market competition, CEB International remained organized and calmly faced the challenge. Through active and effective promotion strategies, a strong order demand foundation was built which strengthened its later sales momentum for the successful IPO of Mediwelcome. The outstanding performance by CEB International team drove the enthusiastic subscription atmosphere for Mediwelcome in the capital market, and finally achieved over 100 times of oversubscription, assisting clients in successfully completing this issuance.
As an international investment banking platform wholly-owned by China Everbright Bank in Hong Kong, CEB International has been paying close attention to and serving China's new economy, and is committed to becoming a bridge connecting China's leading enterprises with the international capital market, which will help more high-quality Chinese enterprises develop further and bloom. The successful listing of Mediwelcome reflects the result of CEBI's hard work in the field of innovative medical services. Relying on diversified business products and abundant customer resources, CEB International will continue to provide Chinese companies with a full range of high-quality financial services including sponsorship and underwriting, investment advisory, and asset management to help China's new economy leading companies develop and grow.
免责声明
请注意光银国际投资有限公司及其下属公司（统称“光银国际”）可能在过去12个月内与上述某些公司有投资银行业务关系或其他业务关系（如配售代理、牵头经办人、保荐人、包销商或自营买卖证券），同时亦可能持有上述公司的财务权益及/或证券或衍生工具。本文章内容及插图仅作资料及一般参考之用，并不构成投资要约或要约邀请，也不是投资、法律、会计、税务或其他意见，任何人士不应根据本文章内容及插图做出任何投资决定，光银国际将不承担任何责任。同时光银国际并不保证本文章已提供所有市场流通信息。本文章属撰文者的意见，不一定与光银国际其他业务领域或部门的意见一致，如有任何修改，恕不另行通知。同时，未经光银国际事先允许，任何人不得全部或部分修改、翻版、分发、转载、复制、发表或引用本文章，光银国际对任何第三方的该等行为保留追述权利。完整免责声明，请见光银国际官方网站：WWW.CEBI.COM.HK
